NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K Filing

NeOnc receives FDA written feedback on CMC development for NEO212 and capsule-to-tablet transition (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $NTHI

Read the full article at SEC EDGAR

More Regulatory news